Background: Atrial fibrillation (AF) is a common cause of stroke. Silent cerebral infarctions (SCIs) are known to occur in the presence and absence of AF, but the association between these disorders has not been well-defined.
A trial fibrillation (AF) is the most common arrhythmia in the elderly, currently affecting more than 2.7 million Americans (1) , with a projected prevalence of 5.6 to 12.1 million by 2050 (2, 3) . Patients with AF have not only a 4-to 5-fold increase in the risk for stroke (4) but also larger brain infarctions and worse poststroke outcomes than patients without AF (5) (6) (7) . A recent meta-analysis demonstrated that AF is associated with a 40% increase in the risk for cognitive impairment (relative risk [RR], 1.40 [95% CI, 1.19 to 1.64]) (8) . This association was independent of a history of symptomatic stroke (RR, 1.34 [CI, 1.13 to 1.58]) (8) and other comorbid conditions, such as advanced age, hypertension, heart failure, and diabetes (9, 10) . These findings highlight the elusiveness of the mechanisms underlying this association and suggest pathways other than symptomatic stroke and shared risk factors listed previously as the underlying cause of this association. One such mechanism may be silent cerebral infarctions (SCIs). Several studies showed a significant association between AF and SCIs in patients without a history of clinically overt stroke (11, 12); however, the few studies that attempted to reproduce similar results did not demonstrate an association (13, 14) .
There is a significant variability in the reported prevalence of SCIs in patients with AF (11, 12) . One source of this heterogeneity may lie in the different methods of diagnosing SCIs. Whereas earlier studies used autopsy (15, 16) or computed tomography (CT) scans (17-19) to identify SCIs, recent studies have used magnetic resonance imaging (MRI) (12, 13) , a more sensitive method, to detect such lesions. It is critical to understand the association between AF and SCIs, not only because it may be a mediating factor in the link between AF and cognitive impairment but also because SCIs may predict future symptomatic strokes and death (20 -23) .
No study has attempted to gather all of the available data in the literature on the association between AF and SCIs and on the prevalence of SCIs in patients with AF. Therefore, we performed a systematic review and metaanalysis of the literature to estimate the association between AF and SCIs and the prevalence of SCIs in patients with AF and no history of symptomatic stroke.
METHODS
An internal study protocol was developed at the Cardiac Arrhythmia Service (Boston, Massachusetts) to perform this review; the protocol was not registered in any database.
Data Sources
Five leading bibliographic databases of biomedical science (MEDLINE [Ovid interface], PsycINFO, Cochrane Library [Ovid SP], CINAHL, and EMBASE) were searched electronically from their inception to 8 May 2014, using text and explosion of medical subject headings (Supplement, available at www.annals.org). One of the investigators designed the search strategies with the help of a trained librarian. In addition, bibliographies of pertinent articles as well as review papers were manually searched. No language restriction was applied. Authors of the included studies were contacted when required data were missing or ambiguous.
Study Selection
Prospective and nonprospective studies reporting the prevalence or incidence of SCIs in patients with AF, as well as prospective and nonprospective studies in which a risk estimate for the association between AF and SCIs was reported or could be calculated, were included in this metaanalysis. Magnetic resonance imaging studies were only included if they acknowledged the exclusion of leukoaraiosis from their analyses, used diffusion-weighted images, or used either hypodensity on fluid-attenuated inversion recovery images or prominent hypodensity on T1-weighted images as an additional criterion to separate leukoaraiosis from SCIs. Exclusion criteria included inappropriate study design (such as reviews, editorials, letters, case series, case reports, and conference proceedings); studies evaluating SCIs after a procedure, such as catheter ablation, coronary artery bypass graft surgery, or cardioversion, in patients with AF; studies with conflicting and inconsistent data in which discrepancies between text and tables could not be resolved by contacting authors or consensus; studies of patients with prosthetic heart valves; studies restricted to patients with mitral stenosis or rheumatic valve disease; studies using transcranial Doppler sonography or electroencephalography for diagnosis of SCIs; and studies of patients with acute stroke or a history of symptomatic stroke.
Data Extraction
Following MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines (24) , studies were initially screened on the basis of titles and abstracts. The full texts of potentially relevant papers were later reviewed. The reference lists of the review papers and studies that met the inclusion criteria were manually searched. Data from individual studies were extracted by 2 independent observers. Discrepancies were resolved by consensus or a third reviewer. The data extraction sheet included the first author; year; study design (prospective vs. nonprospective); study setting and comparison groups; follow-up period (when applicable); population characteristics (age; sex; country; comorbid conditions, particularly history of symptomatic stroke; and medication, particularly anticoagulants); inclusion and exclusion criteria; AF type (paroxysmal vs. persistent); and methods of AF ascertainment (electrocardiography vs. others). The data extraction sheet also included the method of outcome ascertainment (CT, MRI, or autopsy); CT, MRI, or autopsy specifications (such as section thickness or number and thickness of gaps between the slices); categories of SCI size; definition of SCI; total sample size; number of patients with and without AF; number of patients with SCIs within each group; type of RR estimate (odds ratio [OR], risk ratio, or hazard ratio); point estimate and 95% CI; list of variables in the multivariate model; and level of adjustment. We considered adjustment for confounding either at the study design stage (such as restriction and matching) or at the analyses stage (such as stratification or multivariate analyses) to be acceptable. Studies that used an acceptable method to control for at least 5 of the following 6 variables were considered to be at minimal risk of confounding bias: age, sex, hypertension, hyperlipidemia, diabetes mellitus, and significant carotid stenosis. Studies that did not control for 2 or more of these variables were considered at moderate risk of confounding bias, and those with no adjustment for any of the variables were considered at high risk of confounding bias and were excluded from analysis of pooled OR.
Quality Assessment
Because there are no standard criteria to assess the quality of observational studies, we used an adaptation of 2 published checklists (25, 26) and criteria that were applicable and relevant to the eligible studies. Risk for misclassification of AF and SCIs, as well as risk of confounding and selection bias, were assessed using 15 questions (Appendix Table 1 , available at www.annals.org). Not all of the quality criteria were applicable to each study; therefore, to make valid comparisons among studies, we used the ratio of estimated quality score to maximum possible score (Appendix Table 2 , available at www.annals.org). The total score was calculated and a sensitivity analysis was performed, including only studies that met at least 70% of the total possible quality score.
Data Synthesis and Analysis
Silent cerebral infarctions were broadly defined as evidence of brain infarctions on imaging or autopsy with no attributable clinical symptoms (such as neurologic deficits). When possible, SCIs were stratified according to their location as cortical versus noncortical. Cortical infarctions were defined as infarctions in the cerebral cortex with or without extension into the subcortical white matter. In the presence of heterogeneity, we used random-effects models and the profile likelihood method (27) to perform the meta-analysis of the association between AF and SCIs. In the absence of heterogeneity, results from fixed-effects models were reported. Forest plots were used to display and summarize the association between AF and SCIs according to SCI diagnosis methods. The Q statistic was used to test for heterogeneity. The degree of heterogeneity was quantified by I 2 statistics with an I 2 value of 30% to 60% representing a moderate level of heterogeneity (28) . We estimated the prevalence of SCIs in patients with AF for each study using binomial distribution. The PROC GLIMMIX procedure in SAS, version 9.1, was used to estimate pooled prevalence of SCIs in patients with AF according to the method of SCI diagnosis. PROC GLIM-MIX is able to fit generalized linear mixed models to correlated data with nonconstant variability where the response is not necessarily normally distributed (response distribution for the prevalence was specified as binomial). Stata/IC, version 12, was used to perform the remainder of the analyses. The significance level was defined as a P value less than 0.05 for all analyses.
Role of the Funding Source
This review was funded by the Deane Institute for Integrative Research in Atrial Fibrillation and Stroke, Massachusetts General Hospital. The funding source had no role in the design or conduct of the study; collection or analysis of the data; or the decision to submit the manuscript for publication.
RESULTS
Of 1723 titles and abstracts, 105 papers met the criteria for full-text screening. One German (29) and 2 Japanese (30, 31) articles were translated into English. Sixteen papers from the electronic search and 1 from the manual search met the inclusion criteria (Appendix Figure, available at www.annals.org). The prevalence of SCIs was extracted or calculated from 17 studies (9 using MRI, 6 using CT, and 2 using autopsy). However, only 11 studies (5 using MRI, 4 using CT, and 2 using autopsy) reported adjusted risk estimates. 
Definition of SCIs
Silent cerebral infarctions were identified by CT, MRI, or autopsy in 6, 9, and 2 studies, respectively (Appendix Table 4 , available at www.annals.org). Autopsy studies were not sufficiently sensitive to detect small lesions because of thick slices and large interslice gaps. Studies that used CT for diagnosis consistently defined SCIs as hypodense foci. Three CT studies described additional criteria in their definition of SCIs (17, 33, 34). Feinberg (17) and Ezekowitz (33) and their colleagues required the presence of focal dilated sulci to be distinguished from SCIs that manifested as hypodense lesions in a vascular distribution with no mass effect or edema. Zito (34) and Feinberg (17) and their colleagues also separated SCIs from lesions suspicious for leukoaraiosis. However, MRI studies were more variable because of different MRI variables and criteria used for the evaluation of SCIs. With the exception of the study by Hara and colleagues (35) , which did not report the exact criteria used, 2 criteria were common in the definition of SCIs on MRI images in all studies: focal, sharply demarcated hyperintense lesions on T2 and hypointense lesions on T1. A few studies applied additional criteria to distinguish SCIs from dilated Virchow-Robin spaces and leukoaraiosis. Criteria to distinguish SCIs from dilated Virchow-Robin spaces included a lesion size of 3 mm or greater (11-14, 23, 35, 36) and presence of a hyperintense rim around the hypointense lesion on fluidattenuated inversion recovery images (13) . Das and colleagues (11) required the lesion to be of cerebrospinal fluid intensity to distinguish SCIs from leukoaraiosis.
Association Between AF and SCIs in Patients Without a History of Symptomatic Stroke
Eleven studies (5 using MRI, 4 using CT, and 2 using autopsy) reported on the association between AF and SCIs. Autopsy studies were heterogeneous and low-quality; therefore, they were excluded from the meta-analysis of the risk estimates. When CT and MRI studies were combined, 4407 patients (505 with AF and 3902 without AF) were included in the analysis; 230 patients with AF (45.54%) and 610 patients without AF (15.63%) had SCIs. Atrial fibrillation was associated with SCIs in patients with no symptomatic stroke history (OR, 2.62 [CI, 1.81 to 3.80]; I 2 ϭ 32.12%; P for heterogeneity ϭ 0.118) (Figure 1) . The results were robust to further sensitivity analyses (Table 2). There was no significant heterogeneity between MRI and CT studies. Among MRI studies, Marfella and colleagues (12) reported a more significant association between AF and SCI. This could be because the study population had diabetes mellitus, which may have accentuated the vascular effect of AF on the brain. Removing this study did not alter the results significantly. All of the MRI studies that were included in this analysis defined SCI lesions as lesions greater than 3 mm. 
Prevalence of SCIs in Patients With AF and No History of Symptomatic Stroke
Data on the prevalence of SCIs in patients with AF were available in 17 studies (9 MRI, 6 CT, and 2 autopsy). Because the prevalence of SCIs varies depending on the sensitivity of the diagnosis method, we reported SCI prevalence within each diagnosis category (CT, MRI, and autopsy). Autopsy studies were heterogeneous and of low sensitivity; therefore, we did not report a pooled prevalence estimate for these studies. The prevalence of SCIs was highest when lesions were detected by MRI, the most sensitive diagnostic method (prevalence, 0.40 [CI, 0.29 to 0.51]) (Figure 2 ). The prevalence of SCIs in CT scans was lower than the prevalence in MRI scans (prevalence in CT scans, 0.22 [CI, 0.13 to 0.32]) (Figure 2) . One source of heterogeneity among MRI studies may be the variability in prevalence of vascular comorbid conditions ( Table 1) . For instance, the prevalence of diabetes varies from 7% to 100% among studies. The study in which all patients had diabetes reported a higher prevalence of SCI. The removal of this study from the analysis reduced the heterogeneity and the pooled prevalence to 0.31 (CI, 0.25 to 0.38). The mean age of the patients was similar across studies, ranging from 50.0 to 83.6 years. To minimize variability in the definition of SCIs among MRI studies, we also performed a sensitivity analysis limited to 7 MRI studies in which only lesions greater than 3 mm were included in the definition of SCIs (11-14, 23, 36). The prevalence of such lesions in MRI scans was estimated to be 0.44 (CI, 0.33 to 0.57).
Incidence of SCIs in Patients With AF and No History of Symptomatic Stroke
Data on the incidence of SCIs in patients with AF were scarce. Only 3 studies (14, 29, 33) reported longitudinal assessment of SCIs in patients with AF. Because of AF ϭ atrial fibrillation; CT ϭ computed tomography; MRI ϭ magnetic resonance imaging; SCI ϭ silent cerebral infarction. * Studies that used an acceptable method to control for Ն5 of the following 6 variables were considered to be at minimal risk of bias: age, sex, hypertension, hyperlipidemia, diabetes mellitus, and presence of significant carotid stenosis. Studies that did not control for Ն2 variables were considered at moderate risk of bias. † For the purpose of this meta-analysis, we used the reported odds ratio for the association between AF and SCI lesions Ͼ5 mm. ‡ Paroxysmal AF. § Persistent AF. Review Atrial Fibrillation and Silent Cerebral Infarctions the significant variability among these studies in definition of SCIs, method of SCI diagnosis, and medications, we did not pool the results. Ezekowitz and colleagues (33) reported a mean incidence rate of 1.3 per 100 person-years on CT scans. In this study, the incidence of SCI lesions did not differ significantly between patients treated with warfarin or placebo. In the study by Longstreth and colleagues (14) , 1433 patients aged 65 years or older with no baseline MRI lesions were followed for an average of 5 years for development of SCIs. During follow-up, 6 of 26 patients (23%) with AF developed SCIs. The anticoagulation status of these patients was unclear. Strach and colleagues (29) reported the occurrence of new MRI lesions in 3.9% of 51 patients during 12 months of follow-up despite therapeutic anticoagulation.
Variability in AF Type
Only a few studies explicitly differentiated paroxysmal from chronic or persistent AF by describing AF duration. The association between SCIs and paroxysmal AF and persistent AF was adequately described in 2 (12, 19 ) and 3 studies (18, 32, 34) , respectively ( 
Variability in the Quality of Included Studies
The exclusion of studies that met less than 70% of total possible score did not change the results substantially ( Table 2) . With the exception of 3 studies (14, 29, 33) that reported both prevalence and incidence of SCIs in patients with AF, the remaining studies were crosssectional. Two autopsy (15, 16) , 3 MRI (23, 35, 37) , and 1 CT (17) study met less than 70% of the total quality score. No single criterion stood out as the primary problem. However, the potential for misclassification of SCIs and the history of symptomatic stroke, as well as unadjusted analysis, were mainly responsible for a lower quality score. Compared with the MRI studies, less sensitive CT and autopsy studies received lower quality scores because of the greater potential for misclassification of SCIs. 
DISCUSSION
This meta-analysis suggests that SCIs are very common in patients with AF. An SCI can be detected on MRI in 40% of patients with this arrhythmia. In addition, AF was associated with more than a 2-fold increase in the odds for any SCI. This association was independent of AF subtypes (paroxysmal vs. persistent). Restricting the analysis to studies with high-quality scores eliminated the heterogeneity among the studies without changing the results substantially.
The prevalence of MRI-diagnosed SCIs in the general population is between 8% and 28% (39). This prevalence is approximately one half of the estimated prevalence of SCI in the AF population. Although SCIs do not present with acute stroke symptoms, they have been reported to be associated with more than 3-and 2-fold increases in the risk for symptomatic stroke (23) and dementia (40) , respectively. Few studies support a relationship between SCIs and death (21) . Consequently, the higher prevalence of SCI in patients with AF may put this population at a greater risk for cognitive impairment, future stroke, and disability. Additional studies are warranted to identify appropriate preventive and treatment strategies to reduce the incidence of SCI in patients with AF.
Beyond rhythm-control strategies, anticoagulation has been the mainstay for the prevention of thromboembolic complications that may lead to SCI and symptomatic stroke in patients with AF. Although the overwhelming benefits of anticoagulant therapy for the prevention of symptomatic stroke in patients with AF have been extensively demonstrated, its effect on the prevention of SCI is unclear. Two studies included in this meta-analysis did not report any reduction in the incidence of SCI under anticoagulation (29, 33) . In this meta-analysis, we could not report a separate estimate of SCI prevalence as a function of prophylactic anticoagulation or antiplatelet therapy because of a lack of comparable data. Studies that used anticoagulants were more recent and used more sensitive imaging methods, such as MRI; therefore, they reported a higher prevalence of SCI lesions. However, earlier studies investigating patients who were not treated with anticoagulants used less sensitive diagnostic methods and reported lower SCI prevalence; therefore, a valid comparison could not be made between the groups. Future studies will be needed to determine whether anticoagulation is associated with lower SCI incidence and whether such a change in SCI incidence will translate into a reduction in symptomatic stroke, dementia, and death.
Although the determinants of SCI versus symptomatic stroke are not well-defined, smaller lesions in deep white matter are more likely to remain silent, and larger cortical lesions are more likely to become symptomatic (15) . The location of an infarction provides insight into the underlying mechanisms of its formation. Cortical and subcortical wedge-shaped infarctions indicate a thromboembolic mechanism (41, 42) , whereas small infarctions in deep subcortical white matter indicate intrinsic small vessel disease, and junctional or watershed infarctions indicate hypoperfusion often caused by proximal arterial stenoses or cardiogenic shock (43) . In contrast to embolic infarctions, nonembolic infarctions due to intrinsic small vessel disease typically occur in the subcortical white matter and can be confused with leukoaraiosis or chronic white matter hyperintensities that occur secondary to nonacute ischemic mechanisms. Data on the location of SCIs were limited, and the reported associations were unadjusted for potential confounders. Therefore, we could not report separate ORs by SCI location.
This meta-analysis has several strengths. First, we performed a thorough electronic and manual search of the literature, translated non-English studies, extracted data in duplicate, and contacted authors when required data were missing or ambiguous, all of which add assurance to the validity and thoroughness of data gathering in this study. Second, several sensitivity analyses were performed to identify potential sources of heterogeneity and evaluate the robustness of the results reported in this study. Third, we were able to report separate ORs according to AF type and methods of SCI diagnosis. Fourth, the geographic diversity of the studies included in this analysis adds to the generalizability of the results. Last, we performed a thorough quality assessment using 15 criteria, taking into account the potential risk for misclassification of exposure and outcome, as well as risk of confounding and selection bias.
This study also has several limitations. There was significant heterogeneity among autopsy studies. Included studies were mainly cross-sectional, and good-quality longitudinal data were lacking. The quality of included studies was variable; however, a sensitivity analysis restricted to studies that met more than 70% of total possible quality score showed similar results. There was inadequate information on the anticoagulation status of the patients in most studies. Last, the prevalence of MRI-defined SCIs varied depending on the MRI diagnostic criteria. Whereas studies that define SCIs as lesions of any size with low signal intensity on T1-weighted images and high signal intensity on T2-weighted images may overestimate the prevalence of SCIs, those that only consider a fully cavitated lesion of greater than 3 mm with signal intensity similar to cerebrospinal fluid may underestimate their prevalence (44) . Because the former definition does not distinguish among SCIs, dilated Virchow-Robin spaces, and leukoaraiosis, the latter definition is likely to be more specific and accurate, particularly because these 3 entities may have different causes and clinical significance. Although MRI variables (field strength of the magnet, matrix, slice thickness, and gap thickness) differed among studies, it is hard to assess the effect of these differences on the reported prevalence of SCIs. Thick slices with large interslice gaps may result in low detection of small lesions and underestimation of the prevalence of SCIs (44). This discussion highlights the need for a unified definition, similar to the one proposed in Appendix Table 5 (available at www .annals.org), to distinguish SCIs from leukoaraiosis and other lesions, such as dilated perivascular spaces in future studies.
In conclusion, this systematic review and meta-analysis provides strong evidence that AF is associated with more than a 2-fold increase in the odds of SCI. Future longitudinal studies with better adjustment for potential confounders and detailed information on the spatial distribution of lesions, as well as use of anticoagulant and antiplatelet therapy, are warranted to estimate the incidence of SCI lesions in patients with AF using unified SCI diagnostic criteria. Also, randomized clinical trials should be designed to investigate whether SCI diagnosis should be incorporated into the CHADS 2 or CHA 2 DS 2 -VASc scoring system to identify patients who will benefit from anticoagulation. Prospective (1), not prospective (0), or both (1) 3. Were the inclusion and exclusion criteria adequately described?
Web-Only References
Yes (1) (0) 12. Did the investigators distinguish chronic SCIs from leukoaraiosis by colocalizing the hyperintense lesions on T2-weighted images to nonterritorial FLAIR hyperdensity or prominent hypointense lesions (CSF intensity) on T1-weighted images?
Yes (1 or no (0) 13. Was AF documented on Ն1 electrocardiography? Yes (1) or no (0) 14. Did the investigators assess or report carotid stenosis in study patients?
Yes (1) or no (0) 15. Risk of confounding bias? Minimal (2) if studies controlled for Ն5 of following 6 potential confounders: age, sex, hypertension (or blood pressure measurements), DM, hyperlipidemia (or lipid profile measurements), and CAS (or carotid intima-media thickness) either by including these variables in the multivariate model or by ensuring that patients with and without AF were similar or matched on these variables; moderate (1) if studies did not control for Ն2 of these variables; or high (0) if studies did not control for any potential confounders.
AF ϭ atrial fibrillation; CAS ϭ carotid artery stenosis; CT ϭ computed tomography; CSF ϭ cerebrospinal fluid; DM ϭ diabetes mellitus; FLAIR ϭ fluid-attenuated inversion recovery; MRI ϭ magnetic resonance imaging; SCI ϭ silent cerebral infarction. 
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Patients were screened for a history of TIA or stroke before the initial MRI but were not excluded if they had such events; however, they had to be infarction-free on their initial MRI. 
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*
The infarction size in all cases could not be measured because autopsy materials were not available for all cases. † Obtained from searching the brochure of the EMI 1010 CT scan model. ‡ From reference 38.
